LIVIVO - Search results -

Search results

Result 1 - 10 of total 36

Search options

Article ; Online: Missed opportunities in the early detection of HIV infection in patients with sexually transmitted infections: A real-life study.

García de Lomas-Guerrero, José M A / Jiménez-García, Nicolás / Fernández-Sánchez, Fernando / Del Arco-Jiménez, Alfonso / Prada-Pardal, José Luis / de la Torre-Lima, Javier

Enfermedades infecciosas y microbiologia clinica (English ed.)

2024 Volume 42, Issue 3, Page(s) 146–148

Abstract: Introduction: Sexually transmitted diseases such as cervicitis, proctitis and urethritis are associated with high rates of HIV infection. When these pathologies are suspected, HIV serology should be requested.: Material and methods: A retrospective ... ...

Abstract	Introduction: Sexually transmitted diseases such as cervicitis, proctitis and urethritis are associated with high rates of HIV infection. When these pathologies are suspected, HIV serology should be requested. Material and methods: A retrospective study was performed during 2018 at the Hospital Costa del Sol (Marbella, Málaga, Spain). HIV serologies requested in patients who were asked for PCR for Chlamydia trachomatis and Neisseria gonorrhoeae were reviewed. Results: A total of 1818 patients were evaluated, in which HIV serology was performed in 44.7%, of which 14 (1.7%) were positive. The remaining 55.3% were missed diagnostic opportunities. Conclusions: C. trachomatis and N. gonorrhoeae infections are associated with a high rate of occult HIV infection. The degree of suspicion of HIV in this population remains low and it is essential that it be reinforced in the presence of the possibility of infection by these pathologies.
MeSH term(s)	Female ; Humans ; HIV Infections/complications ; HIV Infections/diagnosis ; Gonorrhea/diagnosis ; Gonorrhea/epidemiology ; Retrospective Studies ; Chlamydia Infections/diagnosis ; Chlamydia Infections/epidemiology ; Chlamydia Infections/complications ; Sexually Transmitted Diseases/diagnosis ; Sexually Transmitted Diseases/epidemiology ; Chlamydia trachomatis
Language	English
Publishing date	2024-02-01
Publishing country	Spain
Document type	Journal Article
ISSN	2529-993X
ISSN (online)	2529-993X
DOI	10.1016/j.eimce.2024.01.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: The role of aspirin as antiaggregant therapy in primary prevention. An update.

Jiménez-García, Nicolás / de la Torre Lima, Javier / García Alegría, Javier

Medicina clinica

2019 Volume 153, Issue 8, Page(s) 326–331

Abstract: Aspirin indication in primary prevention has been questioned in the last ten years due to the publication of several trials with neutral outcomes. In the last year, three research studies discussed in this review (ASCEND, ARRIVE, ASPREE) have weighed the ...

Title translation	Papel de la Aspirina® como tratamiento antiagregante en prevención primaria. Puesta al día.
Abstract	Aspirin indication in primary prevention has been questioned in the last ten years due to the publication of several trials with neutral outcomes. In the last year, three research studies discussed in this review (ASCEND, ARRIVE, ASPREE) have weighed the benefit (cardiovascular events reduction) against the adverse effects (especially bleeding) in several situations such as general population with moderate cardiovascular risk, diabetics and elderly population. This review performs a detailed analysis of these trials and it also comments on a recent metanalysis that includes these projects along with others undertaken in the last 30 years. In addition, the current position of aspirin in primary prevention is established based on the latest evidence reviewed.
MeSH term(s)	Aspirin/adverse effects ; Aspirin/therapeutic use ; Cardiovascular Diseases/prevention & control ; Clinical Decision-Making ; Hemorrhage/chemically induced ; Humans ; Platelet Aggregation Inhibitors/adverse effects ; Platelet Aggregation Inhibitors/therapeutic use ; Primary Prevention/methods
Chemical Substances	Platelet Aggregation Inhibitors ; Aspirin (R16CO5Y76E)
Language	Spanish
Publishing date	2019-09-11
Publishing country	Spain
Document type	Journal Article ; Review
ZDB-ID	411607-0
ISSN	1578-8989 ; 0025-7753
ISSN (online)	1578-8989
ISSN	0025-7753
DOI	10.1016/j.medcli.2019.05.024
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.279: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Study on the approach to HIV: health management and the healthcare process in Spain.

De la Torre-Lima, Javier / Oteo, José Antonio / Pinilla, Javier / Mansilla, Rosa / Zamora, Carmen / Ayala Vargas, Victoria / Morillo-Verdugo, Ramón / Moreno, Santiago / Fuster-Ruiz de Apodaca, María José / Pérez-Molina, José A / Colom, Joan

Enfermedades infecciosas y microbiologia clinica (English ed.)

2023 Volume 41, Issue 10, Page(s) 604–611

Abstract: Introduction: HIV continues to represent a problem of great relevance for public health in Spain. This study aims to carry out an analysis that will provide in-depth knowledge of the resources, clinical care, and management during the diagnosis, follow- ... ...

Abstract	Introduction: HIV continues to represent a problem of great relevance for public health in Spain. This study aims to carry out an analysis that will provide in-depth knowledge of the resources, clinical care, and management during the diagnosis, follow-up, and treatment phases of HIV infection in Spain. Methods: In the first phase, a multidisciplinary Scientific Committee designed an information collection tool in the form of a survey. In the second phase, carried out in the autonomous communities of Andalusia, Catalonia, and La Rioja, a multidisciplinary group of 42 experts, representatives of the public administration, clinical profiles, and representatives of NGOs in the field of HIV answered the survey. Results: The assessment of HIV resources is generally positive. As regards diagnosis, the experts considered that there was good coordination between Primary and Hospital care. Regarding treatment, the evaluations reflected good opinions on therapeutic conciliation and adherence, with a negative opinion in the evaluation of drug interactions with antiretroviral treatment. Regarding follow-up, the perception expressed was disparate concerning the coordination between Hospital and Primary Care as well as the adaptation of care to chronicity, aging, fragility, mental health, and oncological processes. Conclusion: There are certain processes that can be improved in the management of HIV infection in people with HIV in Spain, including protocols for follow-up and coordination between primary and hospital care in the treatment and follow-up of the disease.
MeSH term(s)	Humans ; HIV Infections/diagnosis ; HIV Infections/drug therapy ; HIV Infections/epidemiology ; Spain ; Health Facilities ; Surveys and Questionnaires ; Delivery of Health Care
Language	English
Publishing date	2023-01-07
Publishing country	Spain
Document type	Journal Article
ISSN	2529-993X
ISSN (online)	2529-993X
DOI	10.1016/j.eimce.2022.12.008
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: A 23-years old woman with painless skin injuries after a travel to Colombia.

Jiménez-García, Nicolás / Villena Ruíz, María Angeles / Frieyro Elicegui, Marta / De la Torre Lima, Javier

Medicina clinica

2020 Volume 156, Issue 2, Page(s) 104

MeSH term(s)	Adult ; Colombia ; Female ; Humans ; Travel ; Young Adult
Language	Spanish
Publishing date	2020-03-12
Publishing country	Spain
Document type	Journal Article
ZDB-ID	411607-0
ISSN	1578-8989 ; 0025-7753
ISSN (online)	1578-8989
ISSN	0025-7753
DOI	10.1016/j.medcli.2019.11.015
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.279: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks).

Hidalgo-Tenorio, Carmen / Pasquau, Juan / Vinuesa, David / Ferra, Sergio / Terrón, Alberto / SanJoaquín, Isabel / Payeras, Antoni / Martínez, Onofre Juan / López-Ruz, Miguel Ángel / Omar, Mohamed / de la Torre-Lima, Javier / López-Lirola, Ana / Palomares, Jesús / Blanco, José Ramón / Montero, Marta / García-Vallecillos, Coral

Viruses

2022 Volume 14, Issue 3

Abstract: Brief: Real-world data in naïve HIV-1 patients demonstrate that dolutegravir plus lamivudine in a multiple tablet regimen is effective, safe, and satisfactory; it causes moderately increasing weight and abdominal circumference and is administrable on a ... ...

Abstract	Brief: Real-world data in naïve HIV-1 patients demonstrate that dolutegravir plus lamivudine in a multiple tablet regimen is effective, safe, and satisfactory; it causes moderately increasing weight and abdominal circumference and is administrable on a test-and-treat strategy. Background: Our objectives were to determine the real-life effectiveness and safety of DT with dolutegravir (50 mg/QD) plus lamivudine (300 mg/QD) in a multiple-tablet regimen (MTR) in naïve PLHIV followed up for 48 weeks and to evaluate the compliance and satisfaction of patients. Material and methods: An open, single-arm, multicenter, non-randomized clinical trial from May 2019 through September 2020 with a 48-week follow-up. Results: The study included 88 PLHIV patients (87.5% male) with a mean age of 35.9 years; 76.1% were MSM patients. The mean baseline CD4 was 516.4 cells/uL, with a viral load (VL) of 4.49 log10, and 11.4% were in the AIDS stage. DT started within 7 days of first specialist consultation in all patients and the same day in 84.1%; 3.4% had baseline resistance mutations (K103N, V106I + E138A, and V108I); 12.5% were lost to follow-up. At week 48, 86.3% had VL < 50 cop/uL by intention-to-treat analysis and 98.7% by per-protocol (PP) analysis. Virological failure (VF) was recorded in 1.1%, with no resistance mutation. One blip was detected in 5.2% without VF. Three reported anxiety, dizziness, and cephalgia, respectively, at week 4 and one reported insomnia at week 24; none reported adverse events at week 48. The mean weight was 4 kg higher at 48 weeks (p = 0.0001) and abdominal circumference 3 cm larger at 24 weeks (p = 0.022). No forgetfulness occurred in 98.7% of patients. Patient satisfaction was 90/100 at 4, 24, and 48 weeks. Conclusion: Real-world data demonstrate that dolutegravir plus lamivudine in MTR is effective, safe, and satisfactory, moderately increasing weight and abdominal circumference and administrable on a test-and-treat strategy.
MeSH term(s)	Adult ; Anti-HIV Agents/therapeutic use ; Drug Therapy, Combination ; Female ; HIV Infections/drug therapy ; HIV Seropositivity ; HIV-1/genetics ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Homosexuality, Male ; Humans ; Lamivudine/therapeutic use ; Male ; Oxazines ; Piperazines ; Pyridones ; Sexual and Gender Minorities ; Viral Load
Chemical Substances	Anti-HIV Agents ; Heterocyclic Compounds, 3-Ring ; Oxazines ; Piperazines ; Pyridones ; Lamivudine (2T8Q726O95) ; dolutegravir (DKO1W9H7M1)
Language	English
Publishing date	2022-03-04
Publishing country	Switzerland
Document type	Clinical Trial ; Journal Article ; Multicenter Study
ZDB-ID	2516098-9
ISSN	1999-4915 ; 1999-4915
ISSN (online)	1999-4915
ISSN	1999-4915
DOI	10.3390/v14030524
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)

Viruses. 2022 Mar. 04, v. 14, no. 3

2022

Abstract	Brief: Real-world data in naïve HIV-1 patients demonstrate that dolutegravir plus lamivudine in a multiple tablet regimen is effective, safe, and satisfactory; it causes moderately increasing weight and abdominal circumference and is administrable on a test-and-treat strategy. Background: Our objectives were to determine the real-life effectiveness and safety of DT with dolutegravir (50 mg/QD) plus lamivudine (300 mg/QD) in a multiple-tablet regimen (MTR) in naïve PLHIV followed up for 48 weeks and to evaluate the compliance and satisfaction of patients. Material and methods: An open, single-arm, multicenter, non-randomized clinical trial from May 2019 through September 2020 with a 48-week follow-up. Results: The study included 88 PLHIV patients (87.5% male) with a mean age of 35.9 years; 76.1% were MSM patients. The mean baseline CD4 was 516.4 cells/uL, with a viral load (VL) of 4.49 log₁₀, and 11.4% were in the AIDS stage. DT started within 7 days of first specialist consultation in all patients and the same day in 84.1%; 3.4% had baseline resistance mutations (K103N, V106I + E138A, and V108I); 12.5% were lost to follow-up. At week 48, 86.3% had VL < 50 cop/uL by intention-to-treat analysis and 98.7% by per-protocol (PP) analysis. Virological failure (VF) was recorded in 1.1%, with no resistance mutation. One blip was detected in 5.2% without VF. Three reported anxiety, dizziness, and cephalgia, respectively, at week 4 and one reported insomnia at week 24; none reported adverse events at week 48. The mean weight was 4 kg higher at 48 weeks (p = 0.0001) and abdominal circumference 3 cm larger at 24 weeks (p = 0.022). No forgetfulness occurred in 98.7% of patients. Patient satisfaction was 90/100 at 4, 24, and 48 weeks. Conclusion: Real-world data demonstrate that dolutegravir plus lamivudine in MTR is effective, safe, and satisfactory, moderately increasing weight and abdominal circumference and administrable on a test-and-treat strategy.
Keywords	anxiety ; clinical trials ; compliance ; lamivudine ; males ; mutation ; patients ; sleep disorders ; viral load
Language	English
Dates of publication	2022-0304
Publishing place	Multidisciplinary Digital Publishing Institute
Document type	Article
ZDB-ID	2516098-9
ISSN	1999-4915
ISSN	1999-4915
DOI	10.3390/v14030524
Database	NAL-Catalogue (AGRICOLA)

Order via subito

Article ; Online: Clinical and prognostic differences between methicillin-resistant and methicillin-susceptible Staphylococcus aureus infective endocarditis.

Hidalgo-Tenorio, Carmen / Gálvez, Juan / Martínez-Marcos, Francisco Javier / Plata-Ciezar, Antonio / De La Torre-Lima, Javier / López-Cortés, Luis Eduardo / Noureddine, Mariam / Reguera, José M / Vinuesa, David / García, Maria Victoria / Ojeda, Guillermo / Luque, Rafael / Lomas, José Manuel / Lepe, Jose Antonio / de Alarcón, Arístides

BMC infectious diseases

2020 Volume 20, Issue 1, Page(s) 160

Abstract: Background: S. aureus (SA) infective endocarditis (IE) has a very high mortality, attributed to the age and comorbidities of patients, inadequate or delayed antibiotic treatment, and methicillin resistance, among other causes. The main study objective ... ...

Abstract	Background: S. aureus (SA) infective endocarditis (IE) has a very high mortality, attributed to the age and comorbidities of patients, inadequate or delayed antibiotic treatment, and methicillin resistance, among other causes. The main study objective was to analyze epidemiological and clinical differences between IE by methicillin-resistant versus methicillin-susceptible SA (MRSA vs. MSSA) and to examine prognostic factors for SA endocarditis, including methicillin resistance and vancomycin minimum inhibitory concentration (MIC) values > 1 μg/mL to MRSA. Methods: Patients with SA endocarditis were consecutively and prospectively recruited from the Andalusia endocarditis cohort between 1984 and January 2017. Results: We studied 437 patients with SA endocarditis, which was MRSA in 13.5% of cases. A greater likelihood of history of COPD (OR 3.19; 95% CI 1.41-7.23), invasive procedures, or recognized infection focus in the 3 months before IE onset (OR 2.9; 95% CI 1.14-7.65) and of diagnostic delay (OR 3.94; 95% CI 1.64-9.5) was observed in patients with MRSA versus MSSA endocarditis. The one-year mortality rate due to SA endocarditis was 44.3% and associated with decade of endocarditis onset (1985-1999) (OR 8.391; 95% CI (2.82-24.9); 2000-2009 (OR 6.4; 95% CI 2.92-14.06); active neoplasm (OR 6.63; 95% CI 1.7-25.5) and sepsis (OR 2.28; 95% CI 1.053-4.9). Methicillin resistance was not associated with higher IE-related mortality (49.7 vs. 43.1%; p = 0.32). Conclusion: MRSA IE is associated with COPD, previous invasive procedure or recognized infection focus, and nosocomial or healthcare-related origin. Methicillin resistance does not appear to be a decisive prognostic factor for SA IE.
MeSH term(s)	Adult ; Aged ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Cohort Studies ; Diagnostic Tests, Routine ; Endocarditis, Bacterial/diagnosis ; Endocarditis, Bacterial/drug therapy ; Endocarditis, Bacterial/epidemiology ; Endocarditis, Bacterial/microbiology ; Female ; Humans ; Male ; Methicillin-Resistant Staphylococcus aureus/pathogenicity ; Microbial Sensitivity Tests ; Middle Aged ; Prognosis ; Risk Factors ; Staphylococcal Infections/diagnosis ; Staphylococcal Infections/drug therapy ; Staphylococcal Infections/epidemiology ; Staphylococcal Infections/microbiology ; Staphylococcus aureus/drug effects ; Staphylococcus aureus/isolation & purification
Chemical Substances	Anti-Bacterial Agents
Language	English
Publishing date	2020-02-21
Publishing country	England
Document type	Comparative Study ; Journal Article
ISSN	1471-2334
ISSN (online)	1471-2334
DOI	10.1186/s12879-020-4895-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Colonic leishmaniasis in a patient with HIV: a case report.

Soria López, Estela / Olalla Sierra, Julián / Del Arco Jiménez, Alfonso / Pereda Salguero, Teresa / Abitei, Cristina / de la Torre Lima, Javier

Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva

2016 Volume 108, Issue 12, Page(s) 838–840

Abstract: Background: To describe an unusual clinical presentation of visceral leishmaniasis affecting the colon.: Case report: We report the case of an HIV-positive patient with visceral leishmaniasis. We describe the clinical case, the procedures performed, ... ...

Abstract	Background: To describe an unusual clinical presentation of visceral leishmaniasis affecting the colon. Case report: We report the case of an HIV-positive patient with visceral leishmaniasis. We describe the clinical case, the procedures performed, the treatment provided and the patient's evolution. A comparative table of previously reported similar cases is shown. Discussion: Visceral leishmaniasis with intestinal involvement is an uncommon process. Nevertheless, this possibility should be taken into consideration in the differential diagnosis of immunosuppressed patients with symptoms of diarrhea, as a favorable prognosis depends on early diagnosis and appropriate treatment.
MeSH term(s)	Amphotericin B/therapeutic use ; Antiprotozoal Agents/therapeutic use ; Colonic Diseases/complications ; Colonic Diseases/parasitology ; Colonic Diseases/therapy ; HIV Infections/complications ; Humans ; Leishmaniasis, Visceral/complications ; Leishmaniasis, Visceral/parasitology ; Leishmaniasis, Visceral/therapy ; Male ; Middle Aged
Chemical Substances	Antiprotozoal Agents ; Amphotericin B (7XU7A7DROE)
Language	English
Publishing date	2016-12
Publishing country	Spain
Document type	Case Reports ; Journal Article
ZDB-ID	1070381-0
ISSN	1130-0108 ; 0212-7512
ISSN	1130-0108 ; 0212-7512
DOI	10.17235/reed.2016.4038/2015
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 199: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Blood culture-negative infective endocarditis: a worse outcome? Results from a large multicentre retrospective Spanish cohort study.

Suardi, Lorenzo Roberto / de Alarcón, Arístides / García, María Victoria / Ciezar, Antonio Plata / Hidalgo Tenorio, Carmen / Martinez-Marcos, Francisco Javier / Concejo-Martínez, Elena / De la Torre Lima, Javier / Vinuesa García, David / Luque Márquez, Rafael / Ojeda, Guillermo / Reguera Iglesias, José M / Lomas, José M / Lopez-Cortes, Luis E

Infectious diseases (London, England)

2021 Volume 53, Issue 10, Page(s) 755–763

Abstract: Background: To assess the impact of blood cultures negative infective endocarditis (BCNIE) on in-hospital mortality.: Methods: Prospective multicentre study with retrospective analysis of a Spanish cohort including adult patients with definite IE. ... ...

Abstract	Background: To assess the impact of blood cultures negative infective endocarditis (BCNIE) on in-hospital mortality. Methods: Prospective multicentre study with retrospective analysis of a Spanish cohort including adult patients with definite IE. Cardiac implantable devices infection were excluded. Comparisons between blood cultures positive and BCNIE groups were performed to analyse in-hospital mortality. Results: 1001 cases were included of which 83 (8.3%) had BCNIE. Alternative microbiological diagnosis was achieved for 39 (47%) out 83 cases. The most frequent identifications were: Conclusions: In our cohort, BCNIE was not associated to greater in-hospital mortality based in multivariate Cox regression models. The variables most frequently associated with mortality were indicated but not performed surgery (aHR = 2.48, 95% CI 1.73-3.56,
MeSH term(s)	Adult ; Aged ; Blood Culture ; Cohort Studies ; Endocarditis/epidemiology ; Endocarditis, Bacterial/epidemiology ; Hospital Mortality ; Humans ; Prospective Studies ; Retrospective Studies
Language	English
Publishing date	2021-05-26
Publishing country	England
Document type	Journal Article ; Multicenter Study
ZDB-ID	2839775-7
ISSN	2374-4243 ; 2374-4235
ISSN (online)	2374-4243
ISSN	2374-4235
DOI	10.1080/23744235.2021.1925342
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 600: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Dynamics of creatinine estimated glomerular filtration rate using one or more antiretrovirals that inhibit creatinine tubular secretion.

Perez Elias, Maria Jesus / Alejos, Belen / Gutierrez, Maria Mar / Crespo, Manuel / De Los Santos Gil, Ignacio / Ribera, Esteve / Galindo, Maria Jose / Lozano, Fernando / Payeras Cifre, Antonio / Boix, Vicente / Montero-Alonso, Marta / Sanz, José / De La Torre Lima, Javier / Palacios, Rosario / De La Fuente Moral, Sara / Martinez, Esteban

The Journal of antimicrobial chemotherapy

2021 Volume 76, Issue 4, Page(s) 1046–1050

Abstract: Background: Cobicistat, dolutegravir and rilpivirine are all modest inhibitors of proximal tubular creatinine secretion (IPTCrS) and hence a moderate and early non-progressive creatinine estimated glomerular filtration rate (Cr-eGFR) reduction has been ... ...

Abstract	Background: Cobicistat, dolutegravir and rilpivirine are all modest inhibitors of proximal tubular creatinine secretion (IPTCrS) and hence a moderate and early non-progressive creatinine estimated glomerular filtration rate (Cr-eGFR) reduction has been observed in clinical trials. Data regarding the impact of combination of those drugs on Cr-eGFR, in the clinical practice, are scarcely known. Methods: Changes in Cr-eGFR after starting darunavir/cobicistat alone or in combination with dolutegravir and/or rilpivirine were studied in a nationwide retrospective cohort study of consecutive HIV-infected patients initiating darunavir/cobicistat. The relationship between Cr-eGFR changes over time and the use of darunavir/cobicistat alone or darunavir/cobicistat plus dolutegravir and/or rilpivirine adjusted by different HIV patient's characteristics, socio-demographics, HIV severity and use of tenofovir concomitant medication other than antiretrovirals was explored through univariate and multivariate analyses. Results: The analysis included 725 patients. At 48 weeks, the combination of two or more IPTCrS (darunavir/cobicistat with rilpivirine and/or dolutegravir) was associated with higher decreases in Cr-eGFR [adjusted median difference (±SD) -3.5 ± 1.6 (95% CI -6.6 to -0.3), P = 0.047], and a decrease up to or higher than 15 mL/min/1.73 m2 was more frequent [adjusted OR 3.233 (95% CI 1.343-7.782), P = 0.009], with respect to darunavir/cobicistat alone. The Cr-eGFR changes between darunavir/cobicistat and darunavir/cobicistat with rilpivirine and/or dolutegravir showed more significant decreases in patients taking two or more IPTCrS at 12, 24 and 48 weeks. (ClinicalTrials.gov: NCT03042390). Conclusions: Concomitant use of darunavir/cobicistat plus IPTCrS dolutegravir, rilpivirine, or both produced an additive effect in the expected Cr-eGFR decrease.
MeSH term(s)	Anti-HIV Agents/therapeutic use ; Cobicistat/therapeutic use ; Creatinine ; Darunavir/therapeutic use ; Glomerular Filtration Rate ; HIV Infections/drug therapy ; Humans ; Retrospective Studies
Chemical Substances	Anti-HIV Agents ; Creatinine (AYI8EX34EU) ; Cobicistat (LW2E03M5PG) ; Darunavir (YO603Y8113)
Language	English
Publishing date	2021-02-16
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	191709-2
ISSN	1460-2091 ; 0305-7453
ISSN (online)	1460-2091
ISSN	0305-7453
DOI	10.1093/jac/dkaa547
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1197: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 124: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito